乙酰唑胺致肺水肿:基于EudraVigilance数据库的不比例分析
To our knowledge, no prior study has analysed a possible association between acetazolamide and pulmonary oedema. The aim of this study was to use data from the EudraVigilance to detect a safety signal for acetazolamide-induced pulmonary oedema.…
要点
- 乙酰唑胺与肺水肿存在不比例信号,ROR 3.63(95%CI 2.55-5.17)。
- 多数病例为白内障术后单次给药,潜伏期10-90分钟。
- 5例再激发阳性,6例死亡,提示严重风险。
核心结论
- 研究确认乙酰唑胺与严重肺水肿风险相关的信号。
主要发现
- 乙酰唑胺涉及31例肺水肿病例,ROR为3.63(95%CI 2.55-5.17)。
- VigiBase®中也观察到不比例,ROR为4.44(95%CI 3.34-5.90)。
- 超过一半病例为白内障术后单次给药,潜伏期10-90分钟。
- 5例再激发阳性,6例死亡。
临床怎么用
- 临床使用乙酰唑胺时应警惕肺水肿风险,尤其白内障术后单次给药患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To our knowledge, no prior study has analysed a possible association between acetazolamide and pulmonary oedema. The aim of this study was to use data from the EudraVigilance to detect a safety signal for acetazolamide-induced pulmonary oedema. We performed a disproportionality analysis (case-noncase method), calculating reporting odds ratios (RORs) up to 22 February 2024. Among 11 684 208 spontaneous cases of adverse reactions registered in EudraVigilance, 38 275 were pulmonary oedemas. Acetazolamide was involved in 31 cases. In more than half of those cases, the patients received a single dose of acetazolamide after undergoing cataract surgery: latency was 10-90 min. Remarkably, there were five cases of positive rechallenge and six cases resulted in death. The ROR for acetazolamide was 3.63 (95% CI 2.55-5.17). Disproportionality was also observed in VigiBase®: ROR 4.44 (95% CI 3.34-5.90). Our study confirms a signal that suggests a risk of serious pulmonary oedema associated with acetazolamide.
引用
- García M, Albizua Madariaga I, Sainz-Gil M, et al. Acetazolamide-induced pulmonary oedema: A disproportionality analysis from the EudraVigilance database. Br J Clin Pharmacol. 2024. PMID: 38770584. doi:10.1111/bcp.16117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。